Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
| Autor: | Aapro, Ms, VAN WIJK FH, Bolis, G, Chevallier, B, VAN DER BURG ME, Poveda, A, Oliveira, Cf, Tumolo, S, SCOTTO DI PALUMBO, V, Piccart, M, Franchi, M, Zanaboni, F, Lacave, Aj, Fontanelli, R, Favalli, G, Zola, Paolo, Guastalla, Jp, Rosso, R, Marth, C, Nooij, M, Presti, M, Scarabelli, C, Splinter, Ta, Ploch, E, Beex, Lv, Ten, Bokkel, Huinink, W, Forni, M, Melpignano, M, Blake, P, Kerbrat, P, Mendiola, C, Cervantes, A, Goupil, A, Harper, Pg, Madronal, C, Namer, M, Scarfone, G, Stoot, Je, Teodorovic, I, Coens, C, Vergote, I, Vermorken, Jb |
|---|---|
| Přispěvatelé: | University of Groningen, Medical Oncology |
| Jazyk: | angličtina |
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Combination therapy Health Status medicine.medical_treatment cisplatin endometrial carcinoma chemotherapy Gastroenterology doxorubicin CLINICAL-TRIAL randomised clinical trial SDG 3 - Good Health and Well-being Internal medicine Antineoplastic Combined Chemotherapy Protocols polycyclic compounds Humans Medicine ONCOLOGY-GROUP Doxorubicin Infusions Intravenous COMBINATION Aged Gynecology Chemotherapy Antibiotics Antineoplastic Performance status business.industry Hazard ratio Combination chemotherapy ADENOCARCINOMA Hematology Middle Aged 1ST-LINE CHEMOTHERAPY Prognosis Survival Analysis phase III Endometrial Neoplasms Regimen Treatment Outcome Oncology Toxicity Female business PHASE-II TRIAL medicine.drug |
| Zdroj: | Annals of Oncology, 14(3), 441-448. Oxford University Press Annals of Oncology, 14, 441-448. Elsevier Ltd. |
| ISSN: | 0923-7534 |
| Popis: | Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. Patients and methods: Eligible patients had histologically-proven advanced and/or recurrent endometrial adenocarcinoma and were chemo-naive. Treatment consisted of either DOX 60 mg/m(2) alone or CDDP 50 mg/m(2), added to DOX 60 mg/m(2), every 4 weeks. Results: A total of 177 patients were entered and median follow-up is 7.1 years. The combination DOX-CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4 alopecia (72% versus 65%) and nausea/vomiting (36% versus 12%). The combination DOX- CDDP provided a significantly higher response rate than single agent DOX (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|